SCHEMBL914602

SCHEMBL914602

CCOP(=O)(O)Cc1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 1/20 0.42
BTN3A1 O00481 1/20 0.41
POLB P06746 3/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NR1I2 O75469 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.39
HDAC1 Q13547 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
ENPP2 Q13822 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17488978 0.90 PPARD (0.50) PPARDPOLBNR1I2SMN1; SMN2HDAC1
SCHEMBL917064 0.83 NPY5R (0.42) POLBNPC1ALDH1A1KDM4EGAA
SCHEMBL914541 0.83 PPARD (0.44) PPARDBTN3A1POLBNPC1ALDH1A1
SCHEMBL915441 0.83 PPARD (0.44) PPARDPOLBALDH1A1KDM4EMEN1
SCHEMBL915280 0.81 FDPS (0.46) PPARDPOLBNPC1ALDH1A1TDP1
SCHEMBL894078 0.81 ALDH1A1 (0.44) PPARDPOLBALDH1A1KDM4EGAA
SCHEMBL5051393 0.81 KMT2A (0.44) PPARDBTN3A1POLBGAACTDSP1
SCHEMBL12648165 0.81 PPARD (0.42) PPARDPOLBSMN1; SMN2HDAC1ENPP2
SCHEMBL18392890 0.81 MEN1 (0.38) POLBNPC1ALDH1A1KDM4EGAA
SCHEMBL915800 0.81 TSHR (0.52) PPARDPOLBGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250298333-A1 POLYESTER RESIN COMPOSITION, ELECTROSTATIC CHARGE IMAGE DEVELOPING TONER, DEVELOPER, AND IMAGE FORMING METHOD Konica Minolta, Inc. (JP) 2025-09-25 US disclosed
US-7868126-B2 Process for producing polyester, polyester produced using said process, and polyester molded product TOYO BOSEKI KABUSHIKI KAISHA (JP) 2011-01-11 US disclosed
EP-1842868-B1 PROCESS FOR PRODUCING POLYESTER, POLYESTER PRODUCED USING SAID PROCESS, AND POLYESTER MOLDED PRODUCT TOYO BOSEKI (JP) 2010-11-10 EP disclosed
US-20090082529-A1 Polyester, Process for Producing Polyester, and Polyester Molded Article TOYO BOSEKI KABUSHIKI KAISHA (JP) 2009-03-26 US disclosed
US-20080249280-A1 Process for Producing Polyester, Polyester Produced Using Said Process, and Polyester Molded Product TOYO BOSEKI KABUSHIKI KAISHA (JP) 2008-10-09 US disclosed
EP-1932867-A1 POLYESTER, PROCESS FOR PRODUCTION OF POLYESTER, AND POLYESTER MOLDED ARTICLE Toyo Boseki Kabushiki Kasisha (JP) 2008-06-18 EP disclosed
EP-1842868-A1 PROCESS FOR PRODUCING POLYESTER, POLYESTER PRODUCED USING SAID PROCESS, AND POLYESTER MOLDED PRODUCT Toyo Boseki Kabushiki Kasisha (JP) 2007-10-10 EP disclosed
US-20060194790-A1 Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists GONG LEYI 2006-08-31 US disclosed
US-20060189596-A1 Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists GONG LEYI 2006-08-24 US disclosed
US-7081531-B2 Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists ROCHE PALO ALTO LLC (US) 2006-07-25 US disclosed
EP-1599472-A1 CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-11-30 EP disclosed
WO-2004076448-A1 CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-09-10 WO disclosed
US-20040176416-A1 Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists ROCHE PALO ALTO LLC 2004-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189596-A1 Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists CCR3, CCR10, CCR1 PPARD 914/4885BTN3A1 503/4885POLB 3301/4885
US-20040176416-A1 Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists CCR3, CCR1, CCR10 PPARD 2142/4885BTN3A1 654/4885POLB 2689/4885
US-20060194790-A1 Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists CCR3, CCR10, CCR1 PPARD 1155/4885BTN3A1 570/4885POLB 3892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.